Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Monday . Approximately 3,729 shares traded hands during trading, a decline of 41% from the previous session's volume of 6,368 shares.The stock last traded at $8.61 and had previously closed at $8.58.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on PHAR. Oppenheimer upped their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.
View Our Latest Stock Report on PHAR
Pharming Group Price Performance
The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock has a 50-day moving average price of $8.43 and a 200 day moving average price of $8.69. The stock has a market capitalization of $613.57 million, a price-to-earnings ratio of -34.69 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts expect that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
